<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702581</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0073</org_study_id>
    <secondary_id>2020-A02646-33</secondary_id>
    <nct_id>NCT04702581</nct_id>
  </id_info>
  <brief_title>A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery</brief_title>
  <acronym>POLO</acronym>
  <official_title>A Randomized Trial of Delayed Radiotherapy in Patients 1p/19q Codeleted Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because of their prolonged survival, patients with 1p/19q-codeleted low-grade&#xD;
      oligodendrogliomas treated with RT + PCV are at risk of neurocognitive deterioration. We make&#xD;
      the hypothesis that withholding radiotherapy until tumor progression could reduce the risk of&#xD;
      neurocognitive deterioration without impairing overall survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 2030</completion_date>
  <primary_completion_date type="Anticipated">June 2030</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival without neurocognitive deterioration</measure>
    <time_frame>During 9 years</time_frame>
    <description>Survival without neurocognitive deterioration (whatever the cause of deterioration, i.e toxicity or tumor progression) defined as the time from study randomization to failure in any of the 6 cognitive domains that will be explored (i.e memory, working memory, language, visuo-spatial ability, cognitive executive functions, behavioral executive functions) or death due to any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>During 9 years</time_frame>
    <description>Time from study randomization to the time of progression of the tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>During 9 years</time_frame>
    <description>Time from study randomization to the time of death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Oligodendroglioma</condition>
  <condition>Low-grade Oligodendroglioma</condition>
  <condition>1p19q Codeletion</condition>
  <arm_group>
    <arm_group_label>PCV alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 6 cycles of PCV chemotherapy alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT + PCV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy followed by administration of PCV chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCV chemotherapy</intervention_name>
    <description>cycle of PCV chemotherapy is given as:&#xD;
Day 1: CCNU 110 mg/m2 orally;&#xD;
Days 8 and 29: Vincristine 1.4 mg/m2 IV;&#xD;
Days 8 to 21: Procarbazine 60 mg/m2 orally&#xD;
6 cycles are given.</description>
    <arm_group_label>PCV alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiotherapy and PCV chemotherapy</intervention_name>
    <description>Radiotherapy will deliver 50.4 Gy in 28 fractions of 1.8 Gy using IMRT technique.&#xD;
Followed by 6 cycles of PCV chemotherapy&#xD;
1 cycle of PCV is given as:&#xD;
Day 1: CCNU 110 mg/m2 orally;&#xD;
Days 8 and 29: Vincristine 1.4 mg/m2 IV;&#xD;
Days 8 to 21: Procarbazine 60 mg/m2 orally</description>
    <arm_group_label>RT + PCV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Tumor is co-deleted for 1p and 19q based and IDH-mutant (IDH1 or IDH2) according to&#xD;
             local diagnosis&#xD;
&#xD;
          -  Histological confirmation of low-grade oligodendroglioma by central pathological&#xD;
             review according to WHO 2016 classification&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Patients with one or several prior surgical procedure for a low-grade&#xD;
             oligodendroglioma and who undergo a resurgery are eligible if they have not received&#xD;
             prior radiotheray or chemotherapy and if the last histological diagnosis is a&#xD;
             low-grade oligodendroglioma&#xD;
&#xD;
          -  Patients who undergo an initial follow-up after surgery or re-surgery are eligible if&#xD;
             there is no evidence of anaplastic transformation on MRI (no new contrast enhancement,&#xD;
             no obvious modification of the growth rate)&#xD;
&#xD;
          -  Patients requiring an oncological treatment other than surgery because of one or more&#xD;
             of the following characteristics:&#xD;
&#xD;
               -  Progressive disease defined as documented growth prior to inclusion&#xD;
&#xD;
               -  Symptomatic disease defined as the presence of neurological or cognitive symptoms&#xD;
                  or refractory seizures defined as having both persistent seizures interfering&#xD;
                  with everyday life activities other than driving a car and three lines of&#xD;
                  anti-epileptic drug regimen had not worked, including at least one combination&#xD;
                  regimen.&#xD;
&#xD;
               -  Age ≥ 40 and any surgical therapy&#xD;
&#xD;
               -  Age &lt; 40 with prior and subtotal resection or biopsy (i.e., anything less than&#xD;
                  gross total resection)&#xD;
&#xD;
          -  Willing and able to complete neurocognitive examination and the QOL&#xD;
&#xD;
          -  Karnofsky performance status ≥ 60&#xD;
&#xD;
          -  The following laboratory values obtained ≤ 21 days prior to registration:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1500 /mm3&#xD;
&#xD;
          -  Platelet count ≥100,000 / mm3&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT (AST) ≤ 3 x ULN&#xD;
&#xD;
          -  Negative serum or urine pregnancy test done ≤ 7 days prior to registration, for women&#xD;
             of childbearing potential only.&#xD;
&#xD;
          -  Provide informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and nursing women&#xD;
&#xD;
          -  Men or women of childbearing potential who are unwilling to employ adequate&#xD;
             contraception for up to 6 months following the completion of PCV.&#xD;
&#xD;
          -  Received any prior radiation therapy or chemotherapy for any CNS neoplasm.&#xD;
&#xD;
          -  Co-morbid systemic illnesses or other severe concurrent disease which would make the&#xD;
             patient inappropriate for entry into this study or interfere significantly with the&#xD;
             proper assessment of safety and toxicity of the prescribed regimens.&#xD;
&#xD;
          -  Concomitant serious immunocompromised status (other than that related to concomitant&#xD;
             steroids).&#xD;
&#xD;
          -  Uncontrolled intercurrent illness or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
          -  Receiving any other investigational agent which would be considered as a treatment for&#xD;
             the primary neoplasm.&#xD;
&#xD;
          -  Other active malignancy within 5 years of registration. Exceptions: Non-melanotic skin&#xD;
             cancer or carcinoma-in-situ of the cervix.&#xD;
&#xD;
          -  Contra-indication to CCNU: hypersensitivity to CCNU, wheat allergy, association to&#xD;
             yellow fever vaccin&#xD;
&#xD;
          -  Contra-indication to Procarbazine: severe renal failure, severe hepatic failure,&#xD;
             hypersensitivity to procarbazine, association to yellow fever vaccin&#xD;
&#xD;
          -  Contra-indication to Vincristine: hypersensitivity to vincristine, neuromuscular&#xD;
             disorder (for example demyelinating Charcot-Mary Tooth neuropathy), severe renal&#xD;
             failure, severe hepatic failure.&#xD;
&#xD;
          -  Not depending from the french system of health assurance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>François DUCRAY, MD, PhD</last_name>
    <phone>+33(0) 4 72 35 78 06</phone>
    <email>francois.ducray@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cécile TROUBA</last_name>
    <phone>+33(0) 4 72 35 69 15</phone>
    <email>cecile.trouba@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Amiens-Picardie Site Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathieu BOONE, MD</last_name>
      <phone>03 22 45 54 99</phone>
      <email>Boone.mathieu@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Paule AUGEREAU, MD</last_name>
      <phone>02 41 35 27 00</phone>
      <email>paule.augereau@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux Hôpital Saint André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Charlotte BRONNIMANN, MD</last_name>
      <phone>05 56 79 58 08</phone>
      <email>charlotte.bronnimann@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie et Hematologie (ICH) - CHRU Brest, Hopital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Benjamin AUBERGER, MD</last_name>
      <phone>02 98 22 33 95</phone>
      <email>benjamin.auberger@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lien BEKAERT, MD</last_name>
      <phone>02 31 06 46 12</phone>
      <email>bekaert-l@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées PERCY</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Damien RICARD, MD</last_name>
      <phone>01 41 46 68 85</phone>
      <email>damien.ricard@m4x.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur - Hôpitaux civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Guido AHLE, MD</last_name>
      <phone>03 89 12 41 54</phone>
      <email>guido.ahle@ch-colmar.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>François GHIRINGHELLI, MD</last_name>
      <phone>03 80 73 75 06</phone>
      <email>FGhiringhelli@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Roger Salengro CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Apolline MONFILLIETTE, MD</last_name>
      <phone>03 20 44 66 21</phone>
      <email>apolline.djelad@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elise DELUCHE, MD</last_name>
      <phone>05 55 05 61 00</phone>
      <email>elise.deluche@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alice BONNEVILLE-LEVARD, MD</last_name>
      <phone>04 69 16 66 02</phone>
      <email>alice.bonneville-levard@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier CHINOT, MD, PhD</last_name>
      <phone>04 91 38 55 00</phone>
      <email>olivier.chinot@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nice Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Véronique BOURG, MD</last_name>
      <phone>04 92 03 82 80</phone>
      <email>bourg.v@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis, AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoine CARPENTIER, MD, PhD</last_name>
      <phone>01 71 20 74 66</phone>
      <email>antoine.carpentier@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GH Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Caroline DEHAIS, MD</last_name>
      <phone>01 42 16 04 35</phone>
      <email>caroline.dehais@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois site Annecy</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandre TESSIER, MD</last_name>
      <phone>04 50 63 65 93</phone>
      <email>atessier@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elodie VAULEON, MD</last_name>
      <phone>02 99 25 31 82</phone>
      <email>e.vauleon@rennes.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Maxime FONTANILLES, MD</last_name>
      <phone>02 32 08 22 39</phone>
      <email>maxime.fontanilles@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Carole GOURMELON, MD</last_name>
      <phone>02 40 67 99 00</phone>
      <email>carole.gourmelon@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Carole RAMIREZ, MD</last_name>
      <phone>06 62 13 37 01</phone>
      <email>carole.ramirez@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Georges NOEL, MD, PhD</last_name>
      <phone>03 88 25 24 71</phone>
      <email>gnoel@strasbourg.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anna Luisa DI STEFANO, MD</last_name>
      <phone>01 46 25 25 25</phone>
      <email>annaluisadistefano@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elizabeth MOYAL, MD, PhD</last_name>
      <phone>05 31 15 54 45</phone>
      <email>moyal.elizabeth@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Ilyess ZEMMOURA, MD, PhD</last_name>
      <phone>02 18 37 08 13</phone>
      <email>ilyess.zemmoura@univ-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Frederic DHERMAIN, MD</last_name>
      <phone>01 42 11 62 20</phone>
      <email>Frederic.dhermain@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>low-grade oligodendroglioma</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>PCV</keyword>
  <keyword>neurocognitive deterioration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

